The Journal of Immunology, Vol 124, Issue 6 2800-2806, Copyright © 1980 by American Association of Immunologists

ARTICLES

Identification of a major serum DNA-binding protein as factor B of the alternative complement pathway

WD Gardner, JA Haselby and SO Hoch

One of the major proteins in human serum capable of binding DNA has been shown to be factor B of the alternative pathway of complement activation. This protein, designated DNA-binding protein-2 (DBP-2), is recognized by antisera directed against both factor B and its activated form, fragment Bb. Its m.w., charge microheterogeneity, and amino acid composition correspond closely with reported values for those properties of factor B. A radioimmunoassay was used to estimate the serum concentration of DBP-2 at 266 +/- 83 microgram/ml, which also corresponds with the level of factor B normally present in the serum. DBP-2 functions as factor B in the activation of factor B-depleted serum. Limited proteolytic treatment of DBP-2 produced a fragment pattern resembling that of factor B both in the m.w. of the fragments and their electrophoretic mobilities. By means of DNA affinity chromatography of the fragments produced by trypsinization, the DNA- binding domain of DBP-2 was localized.

This article has been cited by other articles:

				C. C. Cunningham, J. T. Holmlund, J. H. Schiller, R. S. Geary, T. J. Kwoh, A. Dorr, and J. Nemunaitis A Phase I Trial of c-Raf Kinase Antisense Oligonucleotide ISIS 5132 Administered as a Continuous Intravenous Infusion in Patients with Advanced Cancer Clin. Cancer Res., May 1, 2000; 6(5): 1626 - 1631. [Abstract] [Full Text]

				S. P. Henry, P. C. Giclas, J. Leeds, M. Pangburn, C. Auletta, A. A. Levin, and D. J. Kornbrust Activation of the Alternative Pathway of Complement by a Phosphorothioate Oligonucleotide: Potential Mechanism of Action J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 810 - 816. [Abstract] [Full Text]

				F. W. Frueh, U. M. Zanger, and U. A. Meyer Extent and Character of Phenobarbital-Mediated Changes in Gene Expression in the Liver Mol. Pharmacol., March 1, 1997; 51(3): 363 - 369. [Abstract] [Full Text] [PDF]